Prevalence and factors associated with inappropriate continuation of stress ulcer prophylaxis at discharge

BMJ Open Qual. 2024 May 10;13(2):e002678. doi: 10.1136/bmjoq-2023-002678.

Abstract

Stress ulcer prophylaxis is started in the critical care unit to decrease the risk of upper gastrointestinal ulcers in critically ill persons and to decrease mortality caused by stress ulcer complications. Unfortunately, the drugs are often continued after recovery through discharge, paving the way for unnecessary polypharmacy.

Study design: We conducted a retrospective cross-sectional study including patients admitted to the adult critical care unit and started on the stress ulcer prophylaxis with a proton pump inhibitor (PPI) or histamine receptor 2 blocker (H2 blocker) with an aim to determine the prevalence of inappropriate continuation at discharge and associated factors.

Result: 3200 people were initiated on stress ulcer prophylaxis, and the medication was continued in 1666 patients upon discharge. Indication for long-term use was not found in 744 of 1666, with a 44% prevalence of inappropriate continuation. A statistically significant association was found with the following risk factors: discharge disposition (home vs other medical facilities, p=0.002), overall length of stay (more than 10 days vs less than or equal to 10 days, p<0.0001), mechanical ventilator use (p<0.001), number of days on a mechanical ventilator (more than 2 days vs less than or equal to 2 days, p<0.001) and class of stress ulcer prophylaxis drug used (H2 blocker vs PPI, p<0.001).

Conclusion: The prevalence of inappropriate continuation was found to be higher than prior studies. Given the risk of unnecessary medication intake and the associated healthcare cost, a web-based quality improvement initiative is being considered.

Keywords: Medication reconciliation; Patient safety; Patient-centred care; Safety culture.

MeSH terms

  • Adult
  • Aged
  • Anti-Ulcer Agents / therapeutic use
  • Cross-Sectional Studies
  • Female
  • Histamine H2 Antagonists* / therapeutic use
  • Humans
  • Inappropriate Prescribing / prevention & control
  • Inappropriate Prescribing / statistics & numerical data
  • Intensive Care Units / organization & administration
  • Intensive Care Units / statistics & numerical data
  • Male
  • Middle Aged
  • Patient Discharge* / standards
  • Patient Discharge* / statistics & numerical data
  • Peptic Ulcer* / epidemiology
  • Peptic Ulcer* / prevention & control
  • Prevalence
  • Proton Pump Inhibitors* / therapeutic use
  • Retrospective Studies
  • Risk Factors

Substances

  • Proton Pump Inhibitors
  • Histamine H2 Antagonists
  • Anti-Ulcer Agents